CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Hyalcis is a biodegradable film designed to prevent the recurrence of malignant pleural mesothelioma after surgery. It releases cisplatin, an anticancer drug, directly at the tumor site, enhancing treatment effectiveness while minimizing toxicity.
Hyalcis is a novel medicinal product, based on an innovative biodegradable film technology, for the prevention of the recurrence after surgery of malignant pleural mesothelioma.
The proposing company, PlumeStars s.r.l., has successfully applied to the European Medical Agency, obtaining in 2016 the orphan designation for Hyalcis.
This entitles PlumeStars as unique provider of the product, i.e, a polymeric film to treat pleura mesothelioma, for which there are no satisfactory curative methods.
To…
PLUMESTARS SRL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
